• Tumors from patients w/CR* had increased gene set enrichment for: B cell receptor antigen activation, PD-1 signaling, TCR signaling, MHC Class II antigen presentation, and antigen processing-cross presentation• IGHG1* enriched expression correlated with higher B cell and helper T cell tumor infiltration and led to ~60% probability of 20–40-month OS and >75% probability of PFS from 10-40 months. Here, IGHG1 is linked to neoplasm.